Foghorn Therapeutics Inc.

FHTX · Nasdaq · Healthcare · Biotechnology

Next earnings: November 4, 2026

$3.50-2.8%Sep 25 close

1M: -41.7%
6M: -22.2%
1Y: -28.0%
5Y: -76.7%

How it compares with its industry

Three ratings, each a percentile against the 585 companies we cover in Biotechnology. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.

Momentum

60of 100 in its industry

Above most of its industry

12 months to a month ago30.5%

6 months to a month ago18.1%

The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.

Value

48of 100 in its industry

Middle of its industry

Profit for the price-31.07%

Cash for the price-40.55%

Sales for the price17.68%

Assets for the price—

Operating profit for the whole business—

Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. Blended from 3 of 5 measures.

Capital allocation

0/1

5 checks not reported

Return on capital—

Shareholder yield—

Share count, 3 years42.8%

Net debt / EBITDA—

Insiders, 12 months—

What management does with the money — scored on whatever the filings answer, never as a share of the total.

The six capital-allocation checks

Return on the money investedNot enough reported to work it out
Debt against earningsNo comparable earnings to measure debt against
Cash returned to shareholdersNeither buybacks nor dividends reported
Share count over three yearsShare count 42.8% higher over three years
Payouts covered by cash flowNot enough reported to compare
Open-market insider buyingNo open-market insider dealing on file

A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.

How it compares with its industry

Momentum

60of 100 in its industry

Above most of its industry

12 months to a month ago30.5%

6 months to a month ago18.1%

Value

48of 100 in its industry

Middle of its industry

Profit for the price-31.07%

Cash for the price-40.55%

Sales for the price17.68%

Assets for the price—

Operating profit for the whole business—

Capital allocation

0/1

5 checks not reported

Return on capital—

Shareholder yield—

Share count, 3 years42.8%

Net debt / EBITDA—

Insiders, 12 months—

What management does with the money — scored on whatever the filings answer, never as a share of the total.

The six capital-allocation checks

Return on the money investedNot enough reported to work it out
Debt against earningsNo comparable earnings to measure debt against
Cash returned to shareholdersNeither buybacks nor dividends reported
Share count over three yearsShare count 42.8% higher over three years
Payouts covered by cash flowNot enough reported to compare
Open-market insider buyingNo open-market insider dealing on file

A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.

How it compares with its industry

How it compares with its industry

Growth & cash — 4 of 5